Ethanol.

Each alcohol dehydrogenase subunit holds a catalytic zinc ion that polarises the alcohol hydroxyl for hydride transfer, so ethanol clearance depends on zinc status. Sustained ethanol intake also raises urinary zinc loss.

Ethanol blocks the intestinal thiamine transporter and slows conversion to thiamine pyrophosphate in the liver, while the metabolic load raises demand for that cofactor. The two move in opposite directions in the same formula.

Alcohol dehydrogenase and aldehyde dehydrogenase each reduce NAD+ to NADH, so ethanol shifts the cellular redox ratio sharply toward NADH. That shift slows fatty acid oxidation and gluconeogenesis until the pool is restored.

Acetaldehyde from ethanol is partly handled by glutathione conjugation, and cysteine availability is the rate-limiting step in making glutathione. NAC restores that substrate pool.

Ethanol metabolism generates acetaldehyde and reactive oxygen species that consume reduced glutathione in the liver. The pairing is a depletion relationship rather than an additive one.

Ethanol lowers expression of the proton-coupled folate transporter in the small intestine and increases urinary folate loss. Folate status falls even when dietary intake holds steady.

Ethanol reduces tubular reabsorption of magnesium, so urinary output rises during and after intake. Magnesium is therefore among the first minerals to fall with regular ethanol exposure.

Kavalactones modulate GABA-A channels and ethanol potentiates the same channel, so together they add to drowsiness and slowed reaction time beyond what either produces alone. Both are also cleared through the liver, which compounds the load.

Valerenic acid acts as a positive modulator at GABA-A receptors, the same site ethanol potentiates. Co-use deepens drowsiness and slows normal alertness more than either alone.

Melatonin sets the timing signal for sleep onset while ethanol fragments the later part of the night and suppresses normal melatonin release. The two pull the same sleep cycle in different directions.

Silymarin raises glutathione availability in hepatocytes and slows lipid peroxidation, the same pressure ethanol metabolism creates. The pairing is long-standing formulation practice, with the human evidence still thin.

Ethanol is the standard tincture solvent because lipophilic constituents such as curcuminoids dissolve far better in a hydroalcoholic base than in water. The solvent ratio sets which constituents the finished extract carries.

Propolis resins and flavonoids are largely insoluble in water, so ethanol is used to pull them into solution and to keep the extract stable. Water-based propolis carries a different and narrower constituent profile.

S-adenosyl-L-methionine is the methyl donor whose regeneration depends on the one-carbon cycle, and ethanol exposure disturbs that cycle. A preclinical study combined SAM-e with B vitamins and reported restored redox markers. The findings are from animals and the markers are laboratory measures. Read the pairing as mechanistic rather than a demonstrated benefit in people.

Choline is oxidised to betaine, which donates a methyl group to homocysteine, so choline and ethanol meet in one-carbon metabolism. A rodent study measured long-term choline metabolite handling after developmental ethanol exposure with postnatal choline supplementation. This is animal work on metabolite markers. It grounds a mechanism, not a human claim.

Arginine is the substrate for nitric oxide synthase and feeds intestinal barrier and hepatic lipid handling. A mouse study reported that arginine altered ethanol-associated changes in liver fat and oxidative markers. The work is non-human and the endpoints are markers. Confidence rests on the mechanism, not on an outcome in people.

Pyridoxal 5-phosphate is the cofactor for cystathionine beta-synthase and cystathionine gamma-lyase, the enzymes that route homocysteine towards cysteine. Ethanol intake is a recognised influence on B6 status and on the enzymes that activate it. Adequate B6 is therefore a requirement of the pathway rather than a countermeasure. This is textbook cofactor biochemistry.

Methionine synthase requires B12 to transfer a methyl group from folate to homocysteine, regenerating methionine. Folate handling is already stored as a partner here and B12 is the other half of the same reaction. Naming one without the other leaves the cycle incomplete. This is settled biochemistry with no combination trial required.

Riboflavin becomes FAD, the cofactor for glutathione reductase and for the flavin-dependent step that converts folate cofactors. Both sit downstream of the redox and one-carbon changes associated with ethanol. Riboflavin status therefore gates how well those pathways run. The relationship is a cofactor requirement, not an interaction.

Retinol is oxidised to retinal by the same alcohol dehydrogenase isoenzymes that oxidise ethanol, so the two are competing substrates. Ethanol also induces CYP2E1, which accelerates the catabolism of retinoids. This is a documented pharmacological competition rather than a formulation choice. It is one reason vitamin A handling is discussed alongside alcohol intake.

Ethanol acts as a positive allosteric modulator at GABA-A receptors, the same inhibitory system that GABA-ergic ingredients target. Combining them stacks sedation in the same direction. This is an anti-synergy worth flagging on any tincture carrying an appreciable alcohol dose. Anyone driving or operating machinery should read it that way.

Passionflower preparations are often supplied as ethanol tinctures and are used for their calming profile, so the vehicle and the botanical push the same way. The additive direction is drowsiness rather than benefit. Formulators should state the alcohol content per serving. This is a caution row, not a recommendation.

Chamomile is commonly extracted into ethanol and its apigenin content interacts with benzodiazepine-site pharmacology in preclinical work. The ethanol vehicle contributes in the same direction. The combination is long-standing tincture practice and the caution is about drowsiness. Alcohol content per serving belongs on the label.

Honokiol and magnolol are described as GABA-A positive modulators in preclinical work, the same site ethanol acts on. Stacking them with an alcohol-based vehicle adds sedation. The preclinical basis is reasonable and human combination data is absent. Flag it rather than formulate around it silently.

Tryptophan is the precursor for serotonin and, downstream, melatonin, and ethanol independently affects serotonergic signalling. The two therefore push sleepiness in the same direction. This is a directional caution drawn from pharmacology, not from a combination study. Confidence is Early on purpose.

Taurine is a sulfur amino acid involved in bile conjugation and cellular osmoregulation, and it appears in animal work on ethanol-associated hepatic markers. It also turns up in mixed drinks by way of energy products. Neither the animal markers nor the co-formulation practice establish an effect in people. Read it as mechanistic.

Lecithin is used to emulsify lipophilic botanical fractions in a water-ethanol liquid so the product stays dispersed on the shelf. Ethanol itself acts as a co-solvent for the same purpose. This is manufacturing chemistry with no physiological claim attached. It belongs in the formulation notes.

Ethanol is oxidised through acetaldehyde to acetate and then to acetyl-CoA, and carnitine esters shuttle acyl groups across the mitochondrial membrane. The two therefore meet at acetyl group handling. This is a mechanistic overlap without human combination data. Confidence stays Early.